Condition: Dry Eye Disease · Sjögren Syndrome · Sponsor: Sylentis, S.A.
This study will examine the efficacy and safety of tivanisiran sodium eye drops versus vehicle after a 2-week run-in phase when dosed once daily for 3 months in subjects with signs and symptoms of dry eye disease (DED) due to Sjögren's Syndrome.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Sylentis Investigative Site | Birmingham, Alabama, United States | — |
| Sylentis Investigative Site | Dothan, Alabama, United States | — |
| Sylentis Investigative Site | Scottsdale, Arizona, United States | — |
| Sylentis Investigative Site | Garden Grove, California, United States | — |
| Sylentis Investigative Site | Glendale, California, United States | — |
| Sylentis Investigative Site | Los Angeles, California, United States | — |
| Sylentis Investigative Site | Newport Beach, California, United States | — |
| Sylentis Investigative Site | Rancho Cordova, California, United States | — |
| Sylentis Investigative Site | San Diego, California, United States | — |
| Sylentis Investigative Site | Torrance, California, United States | — |
| Sylentis Investigative Site | Aurora, Colorado, United States | — |
| Sylentis Investigative Site | Colorado Springs, Colorado, United States | — |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04819269